by Preventive mastectomies could cut thousands of breast cancer cases, according to a study.
Breast distance surgery, also known as mastectomy, is offered to treat breast cancer in some women and can also be recommended for women who are exposed to a high risk as a preventive measure of the disease.
A study showed that if more women were administered preventive mastectomies, around 6,500 breast cancer cases could be cut every year.
Risk-reducing mastectomies (RRM) are currently only women with the BRCA1, BRCA2, Palb2 genes that are associated with a higher risk of breast cancer, said experts.
However, the analysis pointed out that some women with other genes, including ATM, Chek2, Rad51c, Rad51D, which may also be at risk due to a number of other factors, can benefit from RRM if they have a higher risk of illness.
Such other factors can include a family history of breast cancer and the number of children they had, regardless of whether they have breastfed and have the mammography density.
Women in Great Britain have a probability of 11 percent to develop breast cancer throughout their life.
Doctors can calculate the risk of breast cancer using a woman using tools that combine the effects of different risk factors.
“Significant clinical implications”
Researchers at Queen Mary University of London and the London School of Hygiene and Tropical Medicine (LSHTM) found that if health officers were able to identify all women aged 30 to 55 with a 35 percent or higher risk of breast cancer and then all RRM were able to show.
This corresponds to around 11 percent of the 59,000 women in Great Britain, where breast cancer is diagnosed every year.
The academics pointed out that women with one of the other genes associated with breast cancer, which may have a high risk of illness, could possibly be determined by a mechanism with the name “caskadent tests”, in which family members of women are offered genetic tests that are connected via the various genes that are connected to the disease.
The study for economic reviews published in the Jama Oncology Journal says: “The RRM accommodation appears (or more) for women at 30 to 55 years with a lifelong V. risk risk.
“The results could have significant clinical effects to expand access to RRM beyond BRCA1/BRCA2/Palb2 -Pathogenic variant carrier.”
Prof. Ranjit Manchanda, one of the authors of the newspaper and a gynecological oncology professor at Queen Mary University of London, said: “For the first time, we define the risk with which we should offer RRM.
He added: “This could possibly prevent this [around] 6,500 breast cancer cases annually in British women.
“We recommend that more research is carried out to evaluate the acceptance, the recording and long -term results of RRM in this group.”
Women who are exposed to a high risk of breast cancer can also be offered regular screening and medication.
Louise Grimsdell, now a leading clinical nurse specialist in breast cancer, said: “The choice of risk -reducing operation is a complex and deeply personal decision associated with emotional and physical effects.
“Therefore, women can take all their options into account, including screening and risk discovery medication, and are supported by their clinician to make a well-founded decision that is suitable for them.”
